Status:
COMPLETED
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.
Eligibility Criteria
Inclusion
- Histologically proven renal cell carcinoma with metastases
- Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1
Exclusion
- Prior treatment with more than one systemic therapy for metastatic renal cell carcinoma
- History of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00372853
Start Date
November 1 2006
End Date
May 1 2010
Last Update
June 6 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85258
2
Research Site
New Brunswick, New Jersey, United States, 08903
3
Research Site
Cleveland, Ohio, United States, 44195
4
Research Site
Greenville, South Carolina, United States, 29605